Cell and Gene Commercialization

  1. A 5-Step Guide To Achieving Your Biosimilar Milestones On Time 3/24/2025

    As the biologic patent cliff looms, biosimilar developers must strategically plot their approach to development and manufacturing to secure a corner of their market and reach their target patients.

  2. The Future Promise Of Advanced Therapies In Ophthalmology 3/17/2025

    Six years after the first approved gene therapy in ophthalmology, the field is experiencing a surge of activity. Delve into the exciting potential of advanced therapies for eye diseases.

  3. Enabling Investment In Community Hospitals To Improve Patient Access 3/14/2025

    Learn why enabling community hospitals to alleviate system constraints would usher a change in the future of cell and gene therapy delivery.

  4. Mobilizing Community Hospitals To Improve Patient Access To CGTs 3/14/2025

    The patient, product, and value chains for cell and gene therapies are far different than traditional healthcare delivery and requires new and specialized sets of capabilities at hospitals.

  5. Collaboration Leads To CGT Progress At Astellas' West Coast Innovation Center 3/13/2025

    Yoshi Shitaka, outgoing CSO and Richard Wilson, SVP, Primary Focus Lead (Genetic Regulation) at Astellas share how the company's West Coast Innovation Center serves as a central hub for AI, digital transformation, and more.

  6. Arcellx On Designing A Dynamic CAR-T 3/13/2025

    Arcellx's CMO and CTO talk about the company's platform technology, its partnership with Kite, and preparing its lead asset, anito-cel, for commercial launch.

  7. Navigating Patient Access Challenges In Commercializing Your CGT Product 3/10/2025

    Learn how to effectively break down barriers to patient access in cell and gene therapy by enhancing provider education, streamlining coordination, and expanding patient support.

  8. Navigating Patient Access Challenges When Bringing Your CGT Product To Market 2/24/2025

    Bringing cell and gene therapies to market requires more than scientific breakthroughs; manufacturers must navigate complex patient access challenges to ensure these innovations reach those in need.

  9. The United States' Pioneering Role in Cell and Gene Therapy 2/10/2025

    The United States has been a pioneer in cell and gene therapy and continues to dominate it, driven by its public and private institutions, research advancements, and strong investor support.

  10. Reflecting On A Milestone Year For Cell And Gene Therapies 2/3/2025

    Examine the significant CGT advancements in 2024, including new approvals for solid tumors and diabetes treatments, as well as the role of AI and logistical improvements in scaling these therapies.